Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DARE-HRT1 in Healthy Postmenopausal Women
NCT05418426Phase 1Completed
- Sponsor
- Daré Bioscience, Inc.
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules, Implantable Devices
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DARE-HRT1 in Vulvovaginal atrophy (VVA) and vasomotor symptoms (3 arms), sponsored by Daré Bioscience, Inc. Primary endpoints: Steady State Concentration for Estradiol at 28 days, Steady State Concentration for Estrone at 28 days and 1 more. Started Aug 2020; status: completed.
02
Drugs
DARE-HRT1
03
Conditions
Vulvovaginal atrophy (VVA)vasomotor symptoms
Beyond the preview
Go deeper on NCT05418426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418426.